Allergan Aesthetics Seeks Fifth FDA Approval For BOTOX Cosmetic In Facial Contouring
Allergan Aesthetics, an AbbVie unit (ABBV), said the U.S. FDA accepted for review a supplemental BLA for BOTOX Cosmetic to treat masseter muscle prominence in adults. AbbVie cites two Phase 3 studies (M21-416, M21-417) meeting primary endpoints versus placebo (p=0.0046, p=0.0014) and higher patient satisfaction. If approved, it would be BOTOX Cosmetic’s fifth aesthetic indication.
How this was made
The 30-second read
Why it matters
If approved, BOTOX Cosmetic would become the first and only neurotoxin indicated for MMP in the US, expanding to a fifth aesthetic indication based on two Phase 3 studies meeting primary endpoints.
Market read
Regulatory acceptance plus positive Phase 3 efficacy and satisfaction data can shift approval odds and support valuation expectations for AbbVie’s aesthetics franchise.
What to watch
The article does not mention FDA review timeline, labeling scope details, or any prior regulatory feedback, which are key drivers of near-term risk.
Background
Allergan Aesthetics, an AbbVie company, is seeking a supplemental FDA approval for BOTOX Cosmetic for masseter muscle prominence (MMP) in adults.
Ticker impact
AbbVie’s FDA review was accepted for a supplemental BLA for BOTOX Cosmetic to treat masseter muscle prominence, adding a fifth indication.
Near-term upside bias as traders price in higher odds of approval; magnitude likely moderate until FDA decision timing and any advisory committee signals emerge.
The article discloses a fresh FDA acceptance event plus Phase 3 endpoint and satisfaction results, but it does not provide an approval date or FDA decision outcome.
Market effects
Supports continued demand narrative for aesthetic neurotoxins and reinforces the FDA pathway for additional cosmetic indications.
Primarily US regulatory-driven, with potential spillover to global aesthetics sentiment.
Could strengthen competitive positioning for neurotoxin aesthetics in other markets if US approval follows.
Counterpoint
FDA acceptance does not equal approval; traders may fade the move if the FDA requests additional data or if the approval timeline slips.
Key entities
- companyAbbVie
Sponsor of Allergan Aesthetics and the supplemental Biologics License Application for BOTOX Cosmetic’s MMP indication.
- productBOTOX Cosmetic
Neurotoxin aesthetic product whose label is being expanded to include masseter muscle prominence if FDA approves.
- regulatorU.S. FDA
Accepted the supplemental BLA for review, moving the program into formal regulatory evaluation.
